ClinicalTrials.gg
RecruitingNCT06548906Updated Aug 12, 2024

A Study of GZR4 Injection at Different Injection Sites

A Phase 1 interventional study of GZR4 Injection in Healthy Subjects, sponsored by Gan and Lee Pharmaceuticals, USA. Recruiting at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled May 2024, registered Aug 2024).
  • Started May 2024; still recruiting 2 years 6 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This trial is conducted in China. This study is a randomized, single-center, open, three-period crossover trial in healthy subjects to compare the PK, PD, and safety of a single administration of GZR4 at different injection sites (abdomen, deltoid region of upper arm, and thigh).

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Gan and Lee Pharmaceuticals, USA is the lead sponsor of 29 studies on the registry; 5 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Signing the form (ICF) before the trial, fully understanding the trial content, process and possible adverse reactions, and being able to comply with the and restrictions specified in this protocol.
    1. A Male adult subjects aged 18-55 years old.
    1. (BMI) between 19.0-24.0 kg/m2

Exclusion criteria

Exclusion Criteria:

    1. Known or suspected to medical product(s) or related products.
    1. Participation in a clinical study of another study drug within 3 months prior to randomization.
    1. Physical examination, vital signs, laboratory examination, imaging examination, 12-lead and other auxiliary examination results that the researchers considered abnormal clinical significance during screening.
    1. Donation of blood or blood products (more than 100mL) or significant blood loss (more than 200 mL) within 6 months prior to screening
    1. More than 14 units of alcohol per week within 3 months prior to randomization
    1. Smoking more than 5 cigarettes per day within 3 months prior to randomization
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    GZR4 Injection- Abdomen

    Participants received GZR4 Injection by subcutaneous injection on Abdomen.

    Drug: GZR4 Injection

  • Experimental
    GZR4 Injection- Upper Arm

    Participants received GZR4 Injection by subcutaneous injection on Upper Arm.

    Drug: GZR4 Injection

  • Experimental
    GZR4 Injection- Thigh

    Participants received GZR4 Injection by subcutaneous injection on Thigh.

    Drug: GZR4 Injection

Interventions

  • DrugGZR4 Injection

    GZR4 Injection administered sc, once weekly.

06

What researchers measure

Primary outcomes

  1. AUC0-672h

    Area Under the Concentration Versus Time Curve of GZR4 Injection From Time Zero to 672 hours

    Time frame: From Predose to 672 hours after a single dose

Secondary outcomes

  1. AUC0-∞

    Area Under the Concentration Versus Time Curve of GZR4 Injection From Time Zero to Infinity

    Time frame: From Predose to 672 hours after a single dose

  2. Cmax

    Maximum Concentration of GZR4 Injection

    Time frame: From Predose to 672 hours after a single dose

07

Study locations

1 of 1 sites recruiting
  • Study Site
    Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Aug 2024, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartActual
May 8, 2024
Primary completionEst.
Aug 31, 2024
CompletionEst.
Aug 31, 2024
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06548906
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
May 8, 2024
Primary completion
Aug 31, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Aug 12, 2024

Study contacts

wei zhao, PhD
Contact
wei.zhao@ganlee.com
01056456746
Clinical Transparency
study director · Gan & Lee Pharmaceuticals.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion